Recent News

• 10.30.2025 - Q3 2025 Earnings Call
• 10.30.2025 - Q3 2025 Earnings Call
• 09.25.2025 - Bernstein's 2nd Annual Healthcare Forum
• 09.25.2025 - Bernstein's 2nd Annual Healthcare Forum
• 09.17.2025 - Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
• 09.17.2025 - Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
• 09.17.2025 - Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
• 09.17.2025 - Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
• 09.16.2025 - Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
• 09.16.2025 - Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine

Recent Filings

• 09.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.17.2025 - 4 Statement of changes in beneficial ownership of securities